Spots Global Cancer Trial Database for Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
Official Title: A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)
Study ID: NCT00231166
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102, Boston, Massachusetts, United States
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer, New York, New York, United States
Oregon Health Sciences University, Portland, Oregon, United States
University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102, Philadelphia, Pennsylvania, United States
Fred Hutchinson Cancer Research Center Dept. of FHCRC, Seattle, Washington, United States
Novartis Investigative Site, Herston, Queensland, Australia
Novartis Investigative Site, Prahran, Victoria, Australia
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmeceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
